SOX2 was shown to contribute to the stable reprogramming of melanoma cells to their undifferentiated counterparts that were resistant to inhibitors of the MAPK signaling pathway independently of which of oncogenic mutations in the MAPK pathway (BRAF or NRAS) was present [70], and SOX2-positive cells were reported in melanoma cell populations exerting a drug-tolerant state to combined dabrafenib and trametinib treatment [71]. This evidence concerns the gene SOX2 and melanoma.